Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.
Frequently asked questions
What sector does Ascelia Pharma AB (publ) (ACE) operate in?
Ascelia Pharma AB (publ) belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Ascelia Pharma AB (publ) (ACE) current stock price?
As of the latest data, Ascelia Pharma AB (publ) stock price is SEK 0.53, with a previous close of SEK 0.52. Ascelia Pharma AB (publ) gained SEK 0.01 in the last trading session, representing a 1.54% increase.
What is Ascelia Pharma AB (publ) (ACE) current market capitalization?
Ascelia Pharma AB (publ) market cap is approximately 70.51 million.
What is Ascelia Pharma AB (publ) (ACE) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.50, and the forward EPS is SEK 0.02.
What is Ascelia Pharma AB (publ) (ACE) EBITDA?
Ascelia Pharma AB (publ) EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -12.16 million.
Does Ascelia Pharma AB (publ) (ACE) pay dividends?
No. Ascelia Pharma AB (publ) does not pay a dividend.
What is Ascelia Pharma AB (publ) (ACE) beta (volatility) score?
Ascelia Pharma AB (publ) has a beta of 0.766, indicating lower volatility than the overall market.